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Background/aim: Colchicine is the mainstay of treatment in FMF. However, in daily practice it is not easy to maintain effective
colchicine doses in a substantial number of patients due to its side effects. In this study, we aimed to investigate prevalence and risk
factors for colchicine side effects that limit optimal drug dosing and cause permanent discontinuation.
Materials and methods: All patients were recruited from “FMF in Central Anatolia” (FiCA) cohort, 915 adults with a minimum followup time of 6 months during which they had obeyed all treatment instructions. Demographic and anthropometric data, FMF disease
characteristics, disease severity, complications, and treatment features were recorded on a web-based registry. Prevalence of colchicine
intolerance and characteristics of intolerant patients were analyzed.
Results: Effective colchicine doses cannot be maintained in 172 (18.7%) subjects. Main side effects that limit optimal dosing were
as follows: diarrhea in 99 (10.8%), elevation in transaminases in 54 (5.9%), leukopenia in 10 (%1.1), renal impairment in 14 (1.3%),
myopathy in five (0.5%), and allergic skin reaction in two. Colchicine had to be permanently ceased in 18 (2%) patients because of
serious toxicity. Male sex and obesity were found to be associated with liver toxicity, and having a normal body weight was associated
with diarrhea. Chronic inflammation and proteinuria were more common in colchicine-intolerant patients, and they had reported more
frequent attacks compared to those tolerating optimal doses.
Conclusion: Colchicine intolerance is an important problem in daily clinical practice, mainly due to diarrhea and liver toxicity.
Suboptimal colchicine dosing is associated with complications.
Key words: Colchicine, side effect, intolerance, toxicity, dose, familial Mediterranean fever

1. Introduction
Familial Mediterranean fever (FMF) is the most frequent
autoinflammatory disease (AID), which is characterized
by self-limited episodes of fever, polyserositis, arthritis
and/or erysipelas, like skin rash [1]. FMF is more prevalent
in individuals from Mediterranean populations, especially
Turks, Arabs, non-Ashkenazi Jews, and Armenians, while
there are several hundreds of patients described in nonMediterranean countries. FMF attacks generally last for
1–3 days and impair quality of life. Moreover, some patients
may develop secondary amyloidosis and renal failure
as a consequence of chronic ongoing inflammation [2].
Amyloidosis is an irreversible life- and organ-threatening
complication with reported prevalence of approximately
10% in FMF patients [3].

Colchicine is the mainstay of treatment because of its
proven efficacy in reducing frequency, severity, and duration
of attacks and development of secondary amyloidosis [4–6].
Colchicine is the only drug that prevents the development
of amyloidosis with a minimal recommended dose of 1 mg/
day [2]. Amyloidosis is observed almost invariably in those
patients who do not use colchicine regularly or those with
delayed diagnosis. Risk of amyloidosis is about 1% when
colchicine is used regularly and as high as 50% without
life-time colchicine prophylaxis. About 5–10% of patients
do not respond well to colchicine in terms of controlling
occurrence of debilitating attacks, but colchicine still seems
to be protective against the development of amyloidosis.
Hence, life-time colchicine treatment is mandatory in
patients with FMF, unless a severe toxicity develops [7].
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Colchicine has been used for centuries in the treatment
of gout and is a well-known agent with a narrow therapeutic
index. In appropriate dosages, colchicine is an effective and
safe drug. The recommended dose of colchicine is 1–2.5
mg/day in treatment of FMF; however, despite dose
reduction, a significant proportion of patients cannot
tolerate prescribed doses and continue to suffer from
attacks. Recently, antiinterleukin-1 (anti-IL-1) treatment
has made a breakthrough in the treatment of colchicineresistant patients. However, long-term efficacy and safety
of anti-IL-1 antagonists have not been established, and
their high costs limit their extended use.
The side effects of colchicine are well-defined. The
most common side effects are gastrointestinal intolerance,
diarrhea, nausea, and vomiting in particular [8]. Chronic
colchicine use may cause blood cytopenia, liver dysfunction,
and myopathy [9], especially when combined with other
drugs, such as statins, cyclosporine, and clarithromycin
[10,11]. Although the side effects of colchicine are wellknown, the prevalence and risk factors of its side effects
in FMF have not been studied in any systematic study.
Herein, we aimed to investigate the causes of colchicine
intolerance, obstacles in the determination of the optimal
colchicine dosage and the disease course of colchicineintolerant patients.
2. Materials and methods
2.1. Patients and study design
All patients were recruited from FMF in Central Anatolia
(FiCA) cohort, which is a duplication-disabled, internally
and externally controlled, cross-sectional, multicenter
accessible web-based cohort. FiCA cohort comprised
adult FMF patients who were followed at outpatient
rheumatology clinics of three university hospitals located
in central Turkey and that receive referrals from the whole
county. The study was conducted between January 2018
and December 2018. The diagnosis of FMF was made using
Tel-Hashomer criteria [12]. The study protocol received
institutional review board approval (Date: 25.12.2017,
approval number 2017-622), and all the participants
gave written informed consent in the format required
by the relevant authorities and/or boards. The study was
conducted in compliance with Institutional Review Board/
Human Subjects Research Committee requirements.
Demographic and anthropometric data, FMF disease
features, comorbid conditions (asthma, fibromyalgia,
diabetes, hypertension, thyroid disease, chronic kidney/
liver disease, rheumatological disease), and concomitant
medication usage (antidepressant, antihypertension,
antidiabetic, steroid and nonsteroid antiinflammatory
drugs, mycophenolate mofetil, azathioprine, methotrexate,
leflunomide, sulfasalazine) other than colchicine disease
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complications were meticulously questioned. Laboratory
investigations and genotype data (if available) were
recruited from computer-based health records. FMF
disease severity was assessed by International Severity
Score for FMF (ISSF) [13], and FMF-related damage
was assessed by autoinflammatory disease damage index
(ADDI) [14]. Persistent chronic inflammation was defined
as increased C-reactive protein levels above the normal
limits measured in attack-free periods at least ≥2 weeks
apart and must be present ≥75% of follow-up visits.
2.2. Treatment characteristics and side effects
Used medications along with their doses, colchicine
adherence, and side effects were carefully questioned.
Colchicine intolerance is described as not being able to
increase the dose of colchicine to effective levels to prevent
the occurrence of FMF attacks to “less than one attack
in a 6-month period” and to normalize APR. Minimal
maintenance dosage of colchicine was described as 1 mg/
day, which is required for the prevention of amyloidosis,
and dose increase was allowed up to 2.5 mg per day, which
is the recommended maximal safe dose [2].
Side effects that were accepted clinically significant
were as follows: diarrhea (passing loose stools three or
more times a day), abnormality in liver function tests
[elevation of transaminases more than 2.5 fold of the upper
limit of normal (ULN) (for permanent discontinuation
elevation of 2.5xULN in 5 consecutive visits)]; myopathy
[objective muscle weakness or elevation of a creatine
kinase (CK) level of 3xULN for more than 3 times [15]],
and leukopenia (absolute neutrophil number less than
1500/mm3). Oligospermia is described according to
WHO criteria [16] and further assessed in case of patient
declaration.
Finally, prevalence of all colchicine side effects
was presented, and risk factors for their occurrence
were assessed. Moreover, disease-related damage and
complications between groups were compared.
2.3. Statistical analysis
Statistical analyses were performed by SPSS software v15.0
(Chicago, IL). Categorical variables were presented as
numbers and percentages, and continuous variables were
presented as mean ± standard deviation (SD) or median
(interquartile range: IQR), respectively, according to their
normality of distribution. The conformity of continuous
variables to normal distribution was evaluated by using
visual (histogram and probability graphs) and analytical
methods
(the
Kolmogorov–Smirnov/Shapiro–Wilk
tests). In cases where continuous variables were normally
distributed, Student’s t-test was used; and in other cases,
the Mann–Whitney U test was used for comparisons.
For the determination of the underlying risk factors
for the occurrence of a single side effect, we assessed the
relationship between each variable and that particular side
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effect by comparing their features with tolerant patients.
Variables with significant association with a particular
side effect were then entered into binary logistic regression
analysis, and those that remained significant were retained
in the final model. Age, sex, comorbidities (present or
not), concomitant medications (present or not), literacy,
smoking, and obesity were included in the analyses.
Hosmer–Lemeshow goodness-of-fit statistics were used to
assess model fit. A 5% type I error level was used to infer
statistical significance.
3. Results
Original FiCA cohort comprised 971 patients, but 56
patients were excluded from the current study due to
treatment incompliance. Remaining 915 FMF patients
who had been followed up for ≥6 months were included
in the analysis. The demographic, clinical, and disease
characteristics of patients are summarized in Table 1.
Genetic test results were available for 761 patients, and
common variants are presented in Table 2.
Among all patients, 172 of them had colchicine
intolerance (18.8%). Median used dose of colchicine in the

tolerant group was 1 (1–2) mg, whereas it was 1 (1–1) mg
in the intolerant group (P < 0.001). The most common side
effects causing colchicine intolerance were diarrhea in 99
(9.7%) and liver toxicity in 54 patients (5.3%). Leukopenia
(n=10), myopathy (n=5), nausea (n=4), and skin rash
(n=2) were other reasons for the drug intolerance (Table
3).
In 18 patients (1.9%), because of the serious side effects,
colchicine treatment had to be permanently discontinued.
These patients did not tolerate even 0.5 mg/day doses of
colchicine and were treated with interluekin-1 antagonists.
Intractable diarrhea was the leading reason for permanent
discontinuation in 12 (1.1%) patients, followed by liver
toxicity, which occurred in four patients. Myopathy was
observed in two patients because of severe CK elevation,
which was completely resolved after discontinuation. Male
infertility due to oligospermia was evident in two patients.
Diarrhea was evident in 99 patients and was more
prevalent in those with body mass index (BMI) of <25
kg/m2 and in women. In multivariate regression analysis,
having normal BMI was found to be an independent risk
factor for diarrhea (OR: 3.57 95%CI: 1.9–6.7). Fifty-four

Table 1. Clinical and treatment characteristics of colchicine-tolerant and -intolerant groups.
Colchicine tolerant
N = 743

Colchicine intolerant
N = 172

P

Female n (%)

452 (60.8%)

109 (62.6%)

0.770

Age, years

36.1 ± 11.3

38.59 ± 12.7

0.017

Smoking n (%)
Alcohol usage n (%)

221 (29.7%)
65 (8.7%)

38 ( 26.7%)
13 (7.6%)

0.573
0.739

Education year

11.73 ± 4.12

11.76 ± 4.13

0.600

Age at FMF onset, years

13.71 ± 10.2

14.22 ± 11.65

0.790

FMF disease duration, years

22.43 ± 11.58

24.37 ± 13.21

0.054

Treatment duration, years

11.67 ± 7.89

12.01 ± 8.99

0.510

Number of mutations n (%)
Mutation negative
Single allelic mutation
Biallelic mutation

52 (7%)
235 (41.4%)
332 (58.5%)

8 (5.6%)
60 (42.5%)
81 (57.4%)

0.950

Disease severity n (%)
Mild
Moderate
Severe

383 (51.5%)
324 (43.6%)
36 (4.8%)

61 (35.3%)
84 (48.8%)
27 (15.6%)

Obesity

11.4%

10.6%

0.893

Comorbid disease* n (%)
Hypertension
Chronic kidney disease

179 (24.1%)
71( 9.6%)
7 (0.9%)

63 (36.6%)
27( 15.7%)
20 (11.6%)

0.001
0.028
<0.001

Concomitant medication n (%)

181 (24.4%)

52 (30.2%)

0.538

0.001

*Other than hypertension and chronic kidney disease, the frequency of other comorbidities was similar.
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Table 2. Frequency of the ten most common MEFV gene variants
in the study population.
MEFV gene variants

n (%)

M694V/M694V

215 (28)

M694V/-

98 (13)

M694V/M680I

75 (9.7)

M694V/V726A

49 (6.1)

M694V/E148Q

37 (4.5)

M680I /M680I

24 (3.2)

M680I /-

21 (3.1)

V726A/-

23 (2.8)

M680I /V726A

20 (2.4)

M694V/R761H

13 (1.8)

Table 3. Prevalence of all side effects of colchicine and reasons
for drug discontinuation.
Side effect (n)

All side effects
N = 172*

Permanent cessation
N = 18*

Diarrhea

99

11

Liver toxicity

54

4

Leukopenia

10

1

Muscle toxicity

5

2

Skin reaction

2

-

Nausea

4

-

Infertility

2

-

* some patients had more than one clinically significant side
effect

patients had developed liver toxicity because of elevation in
transaminases. Liver toxicity was more common in those
with BMI ≥ 25 kg/m2, males and increasing age. However,
male sex and obesity were found to be the independent
risk factors for liver toxicity (OR: 2.25, 95%CI: 1.12–4.52
and OR: 2.39, 95%CI: 1.08–5.30), respectively.
Colchicine-intolerant patients had a worse disease
course than colchicine-tolerant patients (Table 4).
Intolerant patients had more attacks, persistent
inflammation, comorbidity, proteinuria, amyloidosis, and
worse ADDI and ISSF scores compared to the colchicinetolerant group.
4. Discussion
In this multicenter, cross-sectional study, prevalence of
colchicine intolerance and risk factors for colchicine side
effects were investigated. Our study was the first study
to show the real-life experience related to colchicine
intolerance. Moreover, it was observed that colchicine
intolerance hampered management of FMF and increased

complications of diseases, such as amyloidosis, as a result
of suboptimal dosing.
Colchicine is the mainstay of treatment of FMF due to
its proven efficacy in prevention of attacks and amyloidosis
even in nonresponsive patients in terms of occurrence
of attacks. Therefore, life-time colchicine prophylaxis is
warranted, unless a severe toxicity develops. Colchicine
intolerant patients are not considered “colchicine
resistant” in EULAR recommendations, and treatment of
these patients is not as clear as it is in colchicine-resistant
patients. Our study has shown that these patients are
suboptimally managed as evidenced by ongoing attacks
and persistently-elevated APRs. About one-third of FMF
patients had persistent elevation of APR, though they
did not report that typical attacks predisposed them
to secondary amyloidosis [17]. Moreover, colchicine
compliance and M694V homozygous mutation are two
main factors related to subclinical inflammation and
amyloidosis [18,19].
There were more patients with elevated APRs and
damage including proteinuria and amyloidosis in the

Table 4. Disease course in colchicine-tolerant and -intolerant patients.
Colchicine Tolerant
N = 743

Colchicine Intolerant
N = 172

P-value

Chronic inflammation n (%)

115 (15.4%)

45 (26.1%)

<0.001

Number of attacks in the last year (median) (IQR)

2 (5)

4 (8)

<0.001

Proteinuria n (%)

44(5.9 %)

20 (11.6%)

0.025

Amyloidosis n (%)

33 (% 4.4)

23 (13.3%)

<0.001

ADDI (median) (IQR)

1 (1)

1 (1)

<0.001

ADDI: autoinflammatory disease damage index, FMF: familial Mediterranean fever
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colchicine-intolerant group. Hence, interventions like
adding antimotility drugs for diarrhea and use of IL-1
antagonists to control persistent inflammation in clinical
practice may prevent them from disease complications.
In our study, the colchicine-intolerant group tended
to have a longer disease duration (P = 0.054), and it is
well known that drug compliance rates drop in chronic
illnesses. Even minimal side effects might reduce
patients’ compliance to treatment [20]. Because it is a
life-long disease and because of the possibility of break in
compliance, FMF patients should be frequently warned
about the regular use of effective doses of colchicine.
There is limited data in the literature about colchicine
intolerance. A few studies reported a compliance ratio of
58–64% to colchicine [21,22]; moreover, so far, no study
has investigated the underlying factors that increase
the rate of intolerance. Diarrhea is among the most
commonly observed side effects, affecting approximately
20% of patients [23]. This side effect can be handled
by dividing the daily dose or use of antimotility agents
[2]. Previously, several mechanisms were proposed
for gastrointestinal intolerance, especially diarrhea,
including drug interactions [24,25]. In a recent study,
12 FMF patients were followed prospectively. Three of
them had steatorrhea, and their jejunal biopsy showed
decreased Na+-K+ adenosine triphosphatase (Na+-K+
ATPase) activity, which was claimed to be responsible
for colchicine toxicity [26]. Also, some of the intestinal
enzyme activities, such as lactase, sucrase, and maltase,
were decreased, which might cause diarrhea. Previously,
antimotility agent use was recommended in patients
with diarrhea [27]. In our cohort, antimotility agents
worked in 12 of 19 patients, who were able to reinstitute
colchicine, but these agents were not tested in all
diarrheic patients. Interestingly, having normal BMI
was found to be associated with diarrhea in our study.
Colchicine is a lipophilic molecule; and in overweightobese patients, the volume of distribution might be
different than normal weight population. At the same
oral dose, altered pharmacokinetics of colchicine due to
obesity may explain the low prevalence of diarrhea.
Liver toxicity is one of the common side effects of
colchicine that cause intolerance. Colchicine was mainly
metabolized by the liver [25] and excreted by biliary
tract entering in enterohepatic pathway [25]. Although
elevation of transaminases is a well-known side effect
of colchicine, there are no data on the mechanism of
toxicity and facilitating factors that increase hepatic
injury. In our study, obesity and male sex were found
to be associated with increased liver toxicity. Nearly all
obese patients had fatty liver, and adding a potential
hepatotoxic drug might increase liver toxicity. Colchicine

was metabolized by CYP3A4 enzymes in the liver [28]. It
was shown that CYP3A4 enzyme activity was higher in
females compared to males as demonstrated by higher
protein and mRNA expression [29], which may explain
increased toxicity seen in males.
In the literature, data on colchicine-related male
infertility were inconsistent [30, 31]. Colchicine
concentration in sperm’s microtubule was 3.000-fold
higher than plasma concentrations [32]. In our study,
two male patients suffered from azoospermia, which was
restored to normal numbers after cessation with similar
reported cases in the literature [31,33].
Use of IL-1 antagonists were recommended by
EULAR in colchicine-intolerant patients [2]. In our
study, nine patients were given IL-1 antagonists due to
severe side effects of colchicine and frequent attacks.
Of these, one patient developed injection site reaction
to anakinra and switched to canakinumab, and the
others continued with anakinra treatment. In the follow
up, eight of nine patients went into remission as it was
evident in the absence of attacks, improved life quality
and normalization of APR levels. Hence, IL-1 antagonists
seem to be effective and well-tolerated in colchicineintolerant patients, and we recommend the use of these
drugs in those with elevated APR and frequent attacks.
Although the long-term efficacy of IL-1 antagonists in
the prevention of secondary amyloidosis has yet to be
determined, sustained normalization of APR levels may
be extrapolated as reduced risk for amyloidosis.
There are some limitations to this study. Since
the study was not prospective, temporal changes in
colchicine tolerance might not be correctly estimated.
Also, diarrhea was not evaluated with objective methods
and was primarily based on patient declaration. Patients’
perception of diarrhea might be different and could
be under- or overexpressed by patients. Yet another
limitation is that some side effects might differ in
different ethnic groups or geographic regions, but our
study included subjects from the same ethnic group.
Also, our study only comprised adult patients and might
not reflect colchicine tolerance of children.
In conclusion, colchicine intolerance is an important
domain in the management of FMF patients. Suboptimal
colchicine dosing due to drug intolerance may yield
development of disease complications due to inadequate
control of attacks and chronic inflammation. Use of IL-1
antagonists in such patients after careful evaluation of
possible contributing factors to intolerance may decrease
the development of future complications.
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